Dominari (NASDAQ:DOMH – Get Free Report) and Cohen & Steers (NYSE:CNS – Get Free Report) are both finance companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.
Volatility & Risk
Dominari has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Cohen & Steers has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500.
Institutional and Insider Ownership
42.5% of Dominari shares are held by institutional investors. Comparatively, 51.5% of Cohen & Steers shares are held by institutional investors. 55.3% of Dominari shares are held by company insiders. Comparatively, 45.4% of Cohen & Steers shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dominari | 1 | 0 | 0 | 0 | 1.00 |
| Cohen & Steers | 1 | 2 | 1 | 0 | 2.00 |
Cohen & Steers has a consensus target price of $78.00, indicating a potential upside of 5.37%. Given Cohen & Steers’ stronger consensus rating and higher possible upside, analysts plainly believe Cohen & Steers is more favorable than Dominari.
Profitability
This table compares Dominari and Cohen & Steers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dominari | -51.61% | -235.37% | -163.66% |
| Cohen & Steers | 28.82% | 27.41% | 19.58% |
Earnings and Valuation
This table compares Dominari and Cohen & Steers”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dominari | $123.10 million | 0.46 | -$22.43 million | ($5.39) | -0.43 |
| Cohen & Steers | $556.12 million | 6.84 | $153.22 million | $3.26 | 22.71 |
Cohen & Steers has higher revenue and earnings than Dominari. Dominari is trading at a lower price-to-earnings ratio than Cohen & Steers, indicating that it is currently the more affordable of the two stocks.
Summary
Cohen & Steers beats Dominari on 13 of the 14 factors compared between the two stocks.
About Dominari
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.
About Cohen & Steers
Cohen & Steers, Inc. is a holding company, which operates as an investment manager specializing in liquid real assets, which include real estate securities, listed infrastructure, commodities, natural resource equities, preferred securities, and other income solutions. It manages investment vehicles, such as institutional accounts, open-end funds and closed-end funds. The company was founded by Martin Cohen and Robert Hamilton Steers in 1986 and is headquartered in New York, NY.
Receive News & Ratings for Dominari Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dominari and related companies with MarketBeat.com's FREE daily email newsletter.
